Catalog11 refs
SS-31
Longevity & MitochondrialtherapeuticAnti-AgingResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
MitochondriaMuscles
Overview
SS-31 (Elamipretide, Bendavia, MTP-131, FORZINITY) is a cell-permeable, mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane and binds tightly to cardiolipin. By stabilizing cardiolipin, it preserves cristae structure, reduces electron leakage that produces reactive oxygen species, and supports more efficient ATP production. It may also modulate membrane surface electrostatics and limit opening of the mitochondrial permeability transition pore. FDA accelerated approval granted September 2025 for Barth syndrome as the first mitochondria-targeted therapeutic.
Primary Uses
Mitochondrial diseases
Heart failure
Age-related conditions
Kidney injury
Neurodegenerative conditions
Barth syndrome
Anti-aging at the cellular level (mitochondrial health)
Barth syndrome (mitochondrial myopathy)
Primary mitochondrial myopathy
Age-related macular degeneration (geographic atrophy)
Kidney disease
Mitochondrial membrane stabilization
Ischemia/reperfusion studies
Muscle fatigue research
Age-related organ dysfunction
Enhanced ATP Production
Oxidative Stress Reduction
Mitochondrial Disease Support
Cardiac Protection
Heart Failure Support
Exercise Tolerance
Age-Related Muscle Function
Cognitive Protection
Cellular Rejuvenation
Barth syndrome treatment (FDA approved as FORZINITY)
Primary mitochondrial myopathy (investigational)
Dry age-related macular degeneration (investigational)
Heart failure (investigational)
Mitochondrial dysfunction
Skeletal muscle strength improvement
Cardiac stroke volume improvement
Protocol Reference
Dose
0.5–1 mg
Frequency
5x Weekly
Half-life
~4 Hours
Route
Subcutaneous
Evidence
Phase 4 / FDA Approved / Phase 2/3 clinical trials; FDA Breakthrough Therapy and Fast Track designations for Barth syndrome / Well Studied / FDA Approved (Accelerated Approval Sept 2025 for Barth syndrome) (disputed)
Research References· 4
Research Models
DogHumanMouse
Also in Longevity & Mitochondrial